Menactra

Menactra is a vaccine used to prevent meningitis in persons aged 9 months to 55 years old.

Menactra Overview

Reviewed: August 7, 2015
Updated: 

Menactra is a vaccine used to prevent meningitis.

Menactra is given as a shot into muscle.

Common side effects of Menactra include tenderness, redness, and swelling at the injection site. 

 

Patient Ratings for

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Uses of Menactra

Menactra is a vaccine used to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135.

Menactra vaccine is approved for use in individuals 9 months through 55 years of age.

Menactra vaccine does not prevent N. meningitidis serogroup B disease.

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

For more information on this medication choose from the list of selections below.

Menactra Drug Class

Menactra is part of the drug class:

Side Effects of Menactra

Side effects reported with Menactra in persons aged 9 months through 12 months old include:

  • tenderness, redness, and swelling at the injection site
  • irritability
  • abnormal crying
  • drowsiness
  • loss of appetite
  • vomiting 
  • fever

Side effects reported with Menactra in persons aged 2 through 55 years old include:

  • pain, redness, hardening, and swelling at the injection site
  • diarrhea
  • decrease in appetite
  • drowsiness (ages 2-10 years of age)
  • irritability (ages 2-10 years of age)
  • joint pain (ages 11-55 years of age)
  • headache (ages 11-55 years of age)
  • fatigue (ages 11-55 years of age)
  • a general feeling of discomfort, illness, or uneasiness (malaise) (ages 11-55 years of age)

Tell your healthcare provider if you have any new or unusual symptoms after you receive Menactra. For a complete list of side effects, ask your health care provider.

To report suspected adverse reactions, contact VAERS at 1-800-822-7967 or http://vaers.hhs.gov.

Menactra Interactions

Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Especially tell your doctor if you take or have received:

  • immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids
  • another vaccine

This is not a complete list of Menactra drug interactions. Ask your doctor or pharmacist for more information. 

Menactra Precautions

Serious side effects have been reported with Menactra including the following:

  • Allergic reactions. Tell your healthcare provider about any signs or symptoms of allergic reactions, which include the following:
    • chest pain
    • swelling of the face, eyes, lips, tongue, arms, or legs
    • difficulty breathing or swallowing
    • rash
  • Fainting. Fainting can occur in association with administration of Menactra.
  • Guillain-Barré Syndrome. Those who have been diagnosed with Guillain-Barré Syndrome, may be at a higher risk of Guillain-Barré Syndrome after receiving Menactra.
  • Limitations of vaccine effectiveness. Vaccination with Menactra may not protect all individuals.
  • Altered immunocompetence. If Menactra is administered to those receiving immunosuppressant therapy, the expected immune response may not be obtained.

Do not get Menactra if you or your child had a severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component of Menactra vaccine.

Menactra Food Interactions

Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Menactra, there are no specific foods that you must exclude from your diet when receiving this medication. 

Inform MD

Tell your healthcare provider if you or your child:

  • had a severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component of Menactra vaccine.
  • are pregnant or plan to become pregnant
  • are breastfeeding
  • have received other vaccines

Tell you doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. 

Menactra and Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant.

The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.

Menactra falls into category C. No studies have been conducted in animals, and no well-controlled studies have been done in pregnant women. Menactra should only be given to a pregnant woman if clearly needed. 

Menactra and Lactation

Tell your doctor is you are breastfeeding or plan to breastfeed. 

It is not known if Menactra crosses into human milk. Because some vaccines can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this vaccine, caution should be exercised when Menactra vaccine is administered to a nursing woman.

Menactra Usage

Menactra is given by a healthcare provider as a shot into the muscle.

 

Menactra Dosage

Menactra is given by a healthcare provider as a shot into the muscle.

Primary vaccination:
  • In children 9 through 23 months of age, Menactra vaccine is given as a 2-dose series three months apart.
  • Individuals 2 through 55 years of age, Menactra vaccine is given as a single dose.

Booster immunization:

  • A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.

 

Menactra Overdose

Menactra is administered by a healthcare provider in a medical setting. It is unlikely that an overdose will occur in this setting. However, if overdoes is suspected, seek emergency medical attention.